Barclays’s Jazz Pharmaceuticals JAZZ Stock Holding History

Barclays’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-37,500	Closed	-$6.66M	–	4884
2021 Q2	$6.66M	Buy	+37,500	New	+$6.5M	﹤0.01%	1419
2018 Q2	–	Sell	-1,400	Closed	-$211K	–	7115
2018 Q1	$211K	Buy	1,400 +1,200	+600%	+$176K	﹤0.01%	4789
2017 Q4	$27K	Buy	+200	New	+$27.7K	﹤0.01%	6134
2017 Q3	–	Sell	-1,900	Closed	-$296K	–	6938
2017 Q2	$296K	Sell	1,900 -16,100	-89%	-$2.46M	﹤0.01%	4020
2017 Q1	$2.61M	Sell	18,000 -128,200	-88%	-$16.7M	﹤0.01%	1826
2016 Q4	$15.9M	Buy	146,200 +200	+0.1%	+$22.3K	0.02%	703
2016 Q3	$17.7M	Hold	146,000	–	–	0.02%	600
2016 Q2	$20.6M	Buy	146,000 +24,500	+20%	+$3.61M	0.03%	510
2016 Q1	$15.8M	Sell	121,500 -600	-0.5%	-$74.7K	0.02%	570
2015 Q4	$17.1M	Buy	122,100 +21,600	+21%	+$2.99M	0.02%	644
2015 Q3	$13.3M	Buy	100,500 +85,500	+570%	+$14.7M	0.02%	792
2015 Q2	$2.64M	Buy	+15,000	New	+$2.69M	﹤0.01%	1997
2015 Q1	–	Sell	-5,000	Closed	-$815K	–	7165
2014 Q4	$815K	Hold	5,000	–	–	﹤0.01%	3384
2014 Q3	$800K	Buy	+5,000	New	+$769K	﹤0.01%	3557
2014 Q2	–	Sell	-30,000	Closed	-$4.14M	–	7695
2014 Q1	$4.14M	Buy	+30,000	New	+$4.52M	﹤0.01%	1856
2013 Q3	–	Sell	-10,000	Closed	-$687K	–	7512
2013 Q2	$687K	Buy	+10,000	New	+$611K	﹤0.01%	3845

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Barclays's JAZZ Position: Q1 2026 in Review

Barclays reduced its Jazz Pharmaceuticals (JAZZ) stake by 72% in Q1 2026, selling an estimated $12M and leaving 26,808 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Barclays first reported a position in JAZZ in Q2 2013 and has held it in 51 quarters since. The position peaked at $19.7M in Q4 2016. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Barclays held 26,808 shares of Jazz Pharmaceuticals worth $5.07M as of Q1 2026.
Barclays sold 68,504 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12M.
Jazz Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1809 holding.
Barclays first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Barclays's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2016.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.